{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:12:57Z","timestamp":1783487577236,"version":"3.55.0"},"reference-count":24,"publisher":"Baishideng Publishing Group Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastrointest Oncol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Pancreatic, periampullary\/ampullary, and choledochal adenocarcinomas are aggressive malignancies with a poor prognosis. Immune checkpoint blockade is a promising treatment option for several tumor types. H long terminal repeat-associating 2 (HHLA2), which is analogous to programmed death-ligand 1 (PD-L1), is a recently discovered member of the B7\/cluster of differentiation 28 family and is expressed in many malignancies.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To analyze the expression of HHLA2 and its association with the pathologic biomarkers that predict sensitivity to immunotherapy.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>Ninety-two adenocarcinoma cases located in the pancreas, ampulla, and distal common bile duct were identified. This study assessed 106 pancreaticoduodenectomy and distal\/total pancreatectomy samples that were delivered to Ankara City Hospital between 2019 and 2021. Immunohistochemistry was conducted to examine the expression of DNA mismatch repair (MMR), PD-L1, and HHLA2 proteins.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>Patients with high HHLA2 expression had a higher mean age than those with low expression. Low HHLA2 expression was associated with high perineural invasion. HHLA2 expression was low in pathological stage T3 (pT) 3 cases and high in pathological stage T1, T2, and T4 cases. There was no correlation between HHLA2 expression and the expression of MMR proteins and PD-L1.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>Evaluation of HHLA2 expression in microsatellite stable and PD-L1-negative tumors may be useful for predicting the response of individuals to immunotherapy and may serve as a novel therapeutic target for immunotherapy in advanced-stage disease.<\/jats:p>","DOI":"10.4251\/wjgo.v16.i3.875","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T02:02:20Z","timestamp":1710208940000},"page":"875-882","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of mismatch repair and immune checkpoint protein profile with histopathological parameters in pancreatic, periampullary\/ampullary, and choledochal adenocarcinomas"],"prefix":"10.4251","volume":"16","author":[{"given":"Arzu Hazal","family":"Ayd\u0131n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i43.4846"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00958-3"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0738-1"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122168"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0114-7"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.06.005"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2018.10.006"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01573"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.11.007"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0755-4"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4293-2"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12135"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.10.022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02719-1"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2174\/1566524018666180308115705"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1040960"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.04.001"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature05610"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-02293-6"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-010-0448-x"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.01.013"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0813-2"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2658"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S160493"}],"container-title":["World Journal of Gastrointestinal Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5204\/full\/v16\/i3\/875.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-5204\/full\/v16\/i3\/875.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T02:04:19Z","timestamp":1710209059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5204\/full\/v16\/i3\/875.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":24,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4251\/wjgo.v16.i3.875","relation":{},"ISSN":["1948-5204"],"issn-type":[{"value":"1948-5204","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}